News

NeurAxon, Inc. to Present at First Annual Boston Biotech R&D Conference October 22, 2008

WALTHAM, MA. October 23, 2008 – NeurAxon, Inc. is pleased to announce that Lawrence Bloch, M.D., J.D., the Company’s Chief Executive Officer, will present at the 2008 BIO Investor Forum in San Francisco on October 30, 2008.

The NeurAxon presentation will be delivered on Thursday, October 30th at 8:30 am in the Pacific Heights room of the Palace Hotel in San Francisco. Dr. Bloch will provide an overview of NeurAxon and its portfolio of novel, proprietary pain therapeutics, including its lead candidate, NXN-188, an oral, first-in-class, selective nNOS inhibitor and 5HT agonist which is currently in development for migraine with aura.

About NeurAxon Inc.
NeurAxon Inc. (www.neuraxon.com) discovers and develops next-generation pain therapeutics focused on its first-in-class selective inhibitors of neuronal nitric oxide synthase (nNOS), an enzyme involved in modulating pain and central nervous system neuronal sensitization.

Contact:
Chris Erdman
MacDougall Biomedical Communications
781-235-3060